QPOP category 2

PreclinicalSmall molecule

NNational University Hospital, Singapore

QPOP category 2 is one of 48 small molecule programs targeting Glioma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

GliomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

86 competitors in Glioma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

23 2

Paraplatin

AAvyxa

Phase 3

14 3

Voranigo

SServier

Phase 3

5 4

Opdivo

Bristol-Myers Squibb

Phase 2

11 5

Camptosar

Pfizer

Phase 2

5 6

Keytruda

Merck & Co.

Phase 2

5 7

Lynparza

AstraZeneca

Phase 2

3 8

Verzenio

Eli Lilly

Phase 2

3 9

Dostarlimab

Incyte

Phase 2

2 10

Oncovin

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Glioma

NCT05532397

Clinical

Trials by Indication[1]

Glioma1 trial

Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma

Recruiting·NNational University Hospital, Singapore·N/A·NCT05532397·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for QPOP category 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QPOP category 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QPOP category 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National University Hospital, Singapore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational University Hospital, Singapore

QPOP category 2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Glioma1 trial

References

Drug Info

Quick Facts

Related News